Publications
5813 Results
- Journal / Conference
- Oncogene Aug 24. doi: 10.1038/s41388-025-03546-2. Online ahead of print
- Year
- 2025
GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer
- Journal / Conference
- European Journal of Cancer Sep 9:227:115694
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID40803104
- Study Number(s)
- CTSU/C80405
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)
- Journal / Conference
- Blood Cancer Journal May 3;15(1):85
- Year
- 2025
- PMID
- PMID40319052
- PMC
- PMC12049410
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024
- Journal / Conference
- Journal of the National Cancer Institute Apr 1;117(4):692-700
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39565908
- PMC
- PMC11972677
- Study Number(s)
- S1609
First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), tip; Abstract # TPS5129 Poster Bd # 318b
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CCTG-PR26
TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized Phase III Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response
- Journal / Conference
- Blood Sep 9:blood.2024027962
- Year
- 2025
- Research Committee(s)
- Myeloma
- PMID
- PMID40925099
- Study Number(s)
- S1702
Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
- Journal / Conference
- ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #3622 poster. Blood (2025) 146 (Supplement 1): 3622
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
- Journal / Conference
- ASH Annual Meeting (December 6-9, 2025, Orlando, FL), #154 oral. Blood (2025) 146 (Supplement 1): 154
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)
- Journal / Conference
- ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #340, oral. Blood (2025) 146 (Supplement 1): 340. 10.1182/blood-2025-340.
- Year
- 2025
- Research Committee(s)
- Leukemia
- Study Number(s)
- MYELOMATCH
Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch
- Journal / Conference
- Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473708
- Year
- 2025
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217